|
|
|
|
| TRADING CENTER |
46.26-0.28 / -0.60%
Gilead Sciences Inc (NASDAQ GS:GILD)
46.540.28 / 0.61
After hours quote
Prev. Close:
46.54
Open:
46.41
High:
47.00
Low:
46.18
Volume:
7,398,600
Volume Avg.:
7,628,900
52wk Range:
40.62 - 53.28
Market Cap (mil):
41,630.53
P/E Ratio:
17.86
Dividend Yield:
N/A
| The Stocks With the Most Potential - MotleyFool.com | |
| Prospecting for Winning Biotechs: Gilead Sciences - MotleyFool.com | |
| GileadÃ?Â?Glaxo Deal Targets Asia - Analyst Blog - Zacks.com | |
| Gilead set to benefit from HIV guidelines - FT.com | |
| Drugs: Cost is the highest barrier for treatments - FT.com | |
| Biotech Calendar: Key Dates for December - at TheStreet.com | |
| A Mostly Meaningless FDA Approval - MotleyFool.com | |
| 7 of the Most Efficient Companies on the Planet - MotleyFool.com | |
| Buy These Stocks and Make Money - MotleyFool.com | |
| 7 All-Star Stocks to Make Your Portfolio Shine - MotleyFool.com | |
| Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program - Business Wire | |
| Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread® for Chronic H... - Business Wire | |
| The Highest Possible Returns. Period. - MotleyFool.com | |
| J&J stays true to its diversified model - FT.com | |
| Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Confer... - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 56.55 | -0.95 / -1.65% | 10.81 |
| CELG | Celgene Corporation | 56.53 | -0.79 / -1.38% | 68.11 |
| BIIB | Biogen Idec Inc | 47.38 | -0.36 / -0.75% | 15.90 |
Short Interest Date:
Nov 13 2009
Short Interest Shares:
20,330,539
Short Interest Ratio:
2.2
Float:
898,959,831
Short Interest as a % of Float:
2.2%
Average Daily Volume:
8,099,700
Outstanding Shares:
899,925,051
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company develops and markets therapies to treat life-threatening infectious diseases, and acquisitions are broadening this focus to include ... (more)
| 2008 Revenue: | $5.3 B | Headquarters: Foster City, CA |
| Employees: | 3,441 | CEO: Dr. John C. Martin, M.D., Ph.D. |
| Net Income: | $2.0 B | Industry: Biotechnology |
| Market Cap: | $41.8 B | Website: www.gilead.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| GILD | 46.26 | -0.28 / -0.60% | 46.54 | 47.00 | 46.18 | Profile Chart News |
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved.
Terms under which this service is provided to you. Privacy Policy
Live Quotes automatically refresh, but individual equities are delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
| Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use. Intraday data is at least 20-minutes delayed. All times are ET. Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data. Fundamental data provided by Morningstar, Inc.. SEC Filings data provided by Edgar Online Inc.. Earnings data provided by FactSet CallStreet, LLC. |
